B-cell non-Hodgkin lymphoma | UniteRare Disease Library

Overview

B-cell non-Hodgkin lymphoma (B-cell NHL) is a heterogeneous group of malignant neoplasms arising from B lymphocytes at various stages of differentiation. This category encompasses a wide spectrum of lymphoma subtypes, including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, mantle cell lymphoma, marginal zone lymphoma, Burkitt lymphoma, and others. These cancers primarily affect the lymphatic system, including lymph nodes, spleen, and bone marrow, but can also involve extranodal sites such as the gastrointestinal tract, skin, central nervous system, and other organs. Key symptoms typically include painless lymph node enlargement (lymphadenopathy), unexplained fever, drenching night sweats, unintentional weight loss (collectively known as 'B symptoms'), fatigue, and sometimes abdominal swelling due to spleen or liver enlargement. Some patients may present with symptoms related to specific organ involvement. The clinical course varies significantly depending on the subtype, ranging from indolent (slow-growing) forms such as follicular lymphoma to highly aggressive types such as Burkitt lymphoma. Treatment depends on the specific subtype, stage, and patient factors. Common therapeutic approaches include combination chemotherapy (such as CHOP regimen), anti-CD20 monoclonal antibody therapy (rituximab), radiation therapy, and in some cases, stem cell transplantation. Newer therapies including CAR-T cell therapy, bispecific antibodies, and targeted agents (such as BTK inhibitors and PI3K inhibitors) have significantly expanded the treatment landscape, particularly for relapsed or refractory disease. Prognosis varies widely by subtype, with some indolent forms managed with watchful waiting and others requiring immediate aggressive treatment.

Also known as:

B-cell NHL

Inheritance

Multifactorial

Caused by a mix of several genes and environmental factors

Age of Onset

Variable

Can begin at different ages, from infancy through adulthood

Orphanet ↗NORD ↗

FDA & Trial Timeline

10 events

Feb 2027Safety and Efficacy of Early Second Infusion of Axi-cel Based on ctDNA for R/R Large B - Cell Lymphoma

Zhujiang Hospital — PHASE1, PHASE2

TrialRECRUITING

May 2026Fully Human Bispecific Anti-CD20, Anti-CD19 CAR T Cells for Patients With Relapsed and/or Refractory B Cell Malignancies

Medical College of Wisconsin — PHASE1

TrialNOT YET RECRUITING

Apr 2026Study of CD19 t-haNK and NAI With Rituximab in Participants With Indolent Non-Hodgkin Lymphoma

ImmunityBio, Inc. — PHASE2

TrialNOT YET RECRUITING

Apr 2026A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers

Eli Lilly and Company — PHASE1

TrialNOT YET RECRUITING

Mar 2026Glofitamab Combined With CAR-T Therapy in R/R DLBCL

Ruijin Hospital — PHASE2

TrialNOT YET RECRUITING

Feb 2026NT-I7 (Efineptakin Alfa), a Long-acting Human IL-7, Post-Axicabtagene Ciloleucel or Post-Lisocabtagene Maraleucel in Subjects With Relapsed/Refractory Large B-cell Lymphoma

Washington University School of Medicine — PHASE1

TrialRECRUITING

Feb 2026Low Dose Epcoritamab Plus GemOx in R/R DLBCL

Hospital Universitario Dr. Jose E. Gonzalez — PHASE2

TrialRECRUITING

Feb 2026N-803 Maintenance Therapy Post CAR T-cell Therapy in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas

University of Utah — PHASE1

TrialNOT YET RECRUITING

Jan 2026A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma

TORL Biotherapeutics, LLC — PHASE1, PHASE2

TrialNOT YET RECRUITING

Jan 2026Epcoritamab in Combination With Loncastuximab Tesirine in Relapsed/Refractory Large B-cell Lymphoma

University of Miami — PHASE2

TrialRECRUITING

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Treatments

No FDA-approved treatments are currently listed for B-cell non-Hodgkin lymphoma.

20 clinical trialsare actively recruiting — trials can provide access to cutting-edge therapies.

View clinical trials →

Clinical Trials

20 recruitingView all trials with filters →

Phase 213 trials

Combination Chemotherapy With or Without Autologous Stem Cell Transplant in Treating Patients With Central Nervous System B-Cell Lymphoma

Phase 2

Active

PI: Tracy Batchelor, MD, MPH (Massachusetts General Hospital) · Sites: Anchorage, Alaska; Anchorage, Alaska +124 more · Age: 18–75 yrs

Pemigatinib in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas

Phase 2

Actively Recruiting

PI: Narendranath Epperla, MD, MS (Huntsman Cancer Institute/ University of Utah) · Sites: Salt Lake City, Utah · Age: 18–99 yrs

Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T

Phase 2

Actively Recruiting

PI: Mengyang Di, MD, PhD (Fred Hutch/University of Washington Cancer Consort) · Sites: Seattle, Washington · Age: 18–99 yrs

DA-EPOCH-R Induction Followed by Nivolumab Consolidation in Newly Diagnosed MYC, BCL2 and/or BCL6 Rearranged HGBL

Phase 2

Active

PI: M. ED Chamuleau, MD PhD (VUmc / HOVON) · Sites: Antwerp; Leuven +22 more · Age: 18–99 yrs

A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL)

Phase 2

Active

PI: Bristol-Myers Squibb (Bristol-Myers Squibb) · Sites: Santa Monica, California; Aurora, Colorado +47 more · Age: 18–99 yrs

To Evaluate Safety and Efficacy of Autologous CD19 Chimeric Antigen Receptor (CAR)-T Cells in Relapsed/Refractory B- Non-Hodgkin Lymphoma (B-NHL)

Phase 2

Actively Recruiting

· Sites: Bandar Tun Razak, Kuala Lumpur · Age: 13–75 yrs

A Combination of Rituximab and CC-99282 as Front-line Therapy for Older Frail Patients With Diffuse Large B-cells Non-Hodgkin Lymphoma Evaluated With a Simplified Geriatric Assessment (sGA): a Phase II Study of the Fondazione Italiana Linfomi (FIL)

Phase 2

Actively Recruiting

PI: Alessandra Tucci, Dr.ssa (UO Ematologia, ASST Spedali Civili di Brescia, Pia) · Sites: Alessandria; Ancona +18 more · Age: 80–99 yrs

A Study of Anakinra to Prevent or Treat Severe Side Effects for Patients Receiving CAR-T Cell Therapy

Phase 2

Active

PI: Jae Park, MD (Memorial Sloan Kettering Cancer Center) · Sites: Hackensack, New Jersey; New York, New York · Age: 18–99 yrs

A Study of TAK-007 in Adults With Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)

Phase 2

Active

PI: Medical Director (Takeda) · Sites: Birmingham, Alabama; Los Angeles, California +13 more · Age: 18–99 yrs

Study of Relapsed/ Refractory B-cell Non- Hodgkin Lymphoma

Phase 2

Actively Recruiting

· Sites: Johannesburg; Pretoria · Age: 18–99 yrs

Comparison of Point-of-care Produced CAR T-cell with Commercial CAR T-cells in Patients with R/R LBCL

Phase 2

Actively Recruiting

PI: T. (Tom) van Meerten (UMCG / HOVON) · Sites: Amsterdam; Groningen +5 more · Age: 18–99 yrs

CAR-T Following ASCT for Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (R/R B-NHL) With High-Risk Prognostic Factors

Phase 2

Actively Recruiting

· Sites: Shanghai · Age: 18–99 yrs

A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL

Phase 2

Actively Recruiting

PI: Jason Westin, MD, MS, FACP (M.D. Anderson Cancer Center) · Sites: Houston, Texas · Age: 18–99 yrs

Other2 trials

Dynamic Monitoring of Plasma ctDNA for Prognostic Assessment in Patients With B-Cell Non-Hodgkin Lymphoma

Active

PI: Xinxin Cao, MD (NCC, CICAMS) · Sites: Beijing · Age: 18–75 yrs

A Study of Efficacy and Safety of Glofitamab in Combination With Salvage Therapy in a Real-world Setting in Chinese Adult Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma.

Actively Recruiting

· Sites: Suzhou, Jiangsu · Age: 18–99 yrs

Specialists

Showing 25 of 75View all specialists →

NM

Narendranath Epperla, MD, MS

COLUMBUS, OH

Specialist

Primary central nervous system lymphoma

PI on 2 active trials2 B-cell non-Hodgkin lymphoma publications

Overview

FDA & Trial Timeline

Treatments

Clinical Trials

Specialists

Treatment Centers

Travel Grants

Community

Latest news about B-cell non-Hodgkin lymphoma

Caregiver Resources

Common questions about B-cell non-Hodgkin lymphoma